These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 12360229)
41. The Human Genome Project and public perception: truth and consequences. Pelias MZ; Markward NJ Emory Law J; 2000; 49(3):837-58. PubMed ID: 12645564 [No Abstract] [Full Text] [Related]
42. Genetics and the common good. Tauer CA Second Opin (Chic); 2001 Oct; (8):14-35. PubMed ID: 16025643 [No Abstract] [Full Text] [Related]
43. Direct-to-consumer marketing of genetic tests: access does not reflect clinical utility. Field A; Krokosky A; Terry SF Genet Test Mol Biomarkers; 2010 Dec; 14(6):731-2. PubMed ID: 21158678 [No Abstract] [Full Text] [Related]
44. When science rides the MTA. Dove A J Clin Invest; 2002 Aug; 110(4):425-7. PubMed ID: 12189233 [No Abstract] [Full Text] [Related]
46. Ethical, legal, and social issues in genetic testing for complex genetic diseases. Andrews L; Zuiker ES Valparaiso Univ Law Rev; 2003; 37(3):793-829. PubMed ID: 15378818 [No Abstract] [Full Text] [Related]
47. Attitudes regarding predictive genetic testing in minors: a survey of European clinical geneticists. Borry P; Goffin T; Nys H; Dierickx K Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):78-83. PubMed ID: 18200522 [TBL] [Abstract][Full Text] [Related]
48. Children and genetics: comparative study of international policy positions. Hirtle M Health Law J; 1998; 6 Spec No():43-81. PubMed ID: 14746061 [No Abstract] [Full Text] [Related]
49. Direct-to-patient BRCA1 testing: the Twoj Styl experience. Gronwald J; Huzarski T; Byrski T; Debniak T; Metcalfe K; Narod SA; LubiĆski J Breast Cancer Res Treat; 2006 Dec; 100(3):239-45. PubMed ID: 16807675 [TBL] [Abstract][Full Text] [Related]
50. Whistling in the wind: patents on genetic research are a reality. It's time to reframe the debate. Caulfield TA; Gold ER Forum Appl Res Public Policy; 2000; 15(1):75-9. PubMed ID: 17333589 [No Abstract] [Full Text] [Related]
51. Malta provides loophole for breast-cancer screen. Check E Nature; 2002 Oct; 419(6909):767. PubMed ID: 12397316 [No Abstract] [Full Text] [Related]
52. Nurses and the pharmaceutical industry: part 1. Olsen DP Am J Nurs; 2009 Jan; 109(1):36-9. PubMed ID: 19112263 [No Abstract] [Full Text] [Related]
54. Genetic testing, genetic medicine, and managed care. Rothstein MA; Hoffman S Wake Forest Law Rev; 1999; 34(3):849-88. PubMed ID: 12664926 [TBL] [Abstract][Full Text] [Related]
55. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Phillips KA; Deverka PA; Hooker GW; Douglas MP Health Aff (Millwood); 2018 May; 37(5):710-716. PubMed ID: 29733704 [TBL] [Abstract][Full Text] [Related]
56. Patients and patents. Cho MK; Merz JF Nature; 1997 Nov; 390(6657):221. PubMed ID: 9384365 [No Abstract] [Full Text] [Related]
57. Blurring lines. The research activities of direct-to-consumer genetic testing companies raise questions about consumers as research subjects. Howard HC; Knoppers BM; Borry P EMBO Rep; 2010 Aug; 11(8):579-82. PubMed ID: 20634807 [TBL] [Abstract][Full Text] [Related]
58. Proposed international guidelines on ethical issues in medical genetics and genetic services (part I). World Health Organization Human Genetics Programme Rev Derecho Genoma Hum; 1998; (8):219-23. PubMed ID: 15839036 [No Abstract] [Full Text] [Related]
59. Identification of genetic susceptibility to common diseases: the case for regulation. Baird PA Perspect Biol Med; 2002; 45(4):516-28. PubMed ID: 12388884 [TBL] [Abstract][Full Text] [Related]
60. Children and genetic identification of talent. Inoue Y; Muto K Hastings Cent Rep; 2011; 41(5):1 p. following 48. PubMed ID: 21980899 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]